Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Upfront Riociguat and Ambrisentan Combination Therapy for Pulmonary Arterial Hypertension: A Safety and Efficacy Pilot Study

Next Previous
Trial Profile

Upfront Riociguat and Ambrisentan Combination Therapy for Pulmonary Arterial Hypertension: A Safety and Efficacy Pilot Study

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 25 Jan 2019

At a glance

  • Drugs Ambrisentan (Primary) ; Riociguat (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use

    • Most Recent Events

    • 25 Apr 2018 New trial record
    • 14 Apr 2018 Primary end point (Change in pulmonary vascular resistance (PVR) at 4 month) has been met as per the results presented at the 38th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.
    • 14 Apr 2018 Results presented at the 38th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top